Oragenics Inc (OGEN) Directors and Executive Officers

Officers & Directors

Robert C. Koski
Director

Bruce Cassidy
Director

Frederick W. Telling
Director

Charles L. Pope
Chairman and Director

Alan W. Dunton
Director

John Gandolfo
Director

Kimberly Murphy
Director

J. Michael Redmond
President and Interim Principal Executive Officer

Janet Huffman
Chief Financial Officer, Secretary and Treasurer

Mayer Hoffman McCann P.C.
St. Petersburg, FL

Cherry Bekaert LLP
Auditor,

Oragenics Inc currently has 3 employees.

News about Oragenics Inc Key Personnel

Oragenics, Inc.: Trailblazing Neurological Solutions with Strategic Vision,

Oragenics, Inc.: Pioneering Neurological Therapeutics Amidst a New Strategic VisionIn the rapidly evolving landscape of biotechnology, few companies have displayed the agility and foresight necessary to adapt and innovate as effectively as Oragenics, Inc. The Sarasota-based biotechnology firm has taken notable strides under the leadership of CEO Janet Huffman, making significant advancements in the treatment of neurological disorders. In its recent Q1 2025 shareholder update, the company not only highlighted its financial progress but also underscored the momentum of its lead candidate, ONP-002, which is set to advance into a pivotal Phase IIa concussion trial.As the global focus on neurological health inten...

Oragenics, Inc.: Overcoming Financial Hurdles to Forge a Path Towards Better Neurological Treatments

Oragenics, Inc., a prominent player in the development of intranasal pharmaceuticals for neurological disorders, has recently announced a public offering to raise funds for its ongoing operations. This move comes at a time when the company has faced significant financial challenges, as reflected in its cumulative net loss and negative return on investment (ROI) in the first quarter of 2024. Analyzing the facts and assessing their impact on the company will shed light on its current situation and potential future prospects.

Oragenics, Inc. recently entered into a placement agency agreement to offer 1,100,000 shares of its common stock (or pre-funded warrants) at $1.00 per share. The public ...